A5089873628- Renal cell carcinoma treatment
- Bladder and Urothelial Cancer Treatments
- Renal and related cancers
- Prostate Cancer Treatment and Research
- Cancer Genomics and Diagnostics
- Multiple and Secondary Primary Cancers
- Urinary and Genital Oncology Studies
- Prostate Cancer Diagnosis and Treatment
- Cancer, Lipids, and Metabolism
- Ferroptosis and cancer prognosis
- Radiomics and Machine Learning in Medical Imaging
- Inflammatory Biomarkers in Disease Prognosis
- Urological Disorders and Treatments
- Economic and Financial Impacts of Cancer
- Cancer Diagnosis and Treatment
- Urologic and reproductive health conditions
- Ureteral procedures and complications
- Cancer Immunotherapy and Biomarkers
- Molecular Biology Techniques and Applications
- Cancer-related molecular mechanisms research
- Metastasis and carcinoma case studies
- MRI in cancer diagnosis
- Renal and Vascular Pathologies
- Genetic factors in colorectal cancer
- Ovarian cancer diagnosis and treatment
National Cancer Center
2016-2025
Memorial Sloan Kettering Cancer Center
2021
University of California, Berkeley
2015
Prostate Cancer UK
2010-2012
National Cancer Center
2010
Palmetto Hematology Oncology
2008
The first interim analysis of the KEYNOTE-564 study showed improved disease-free survival with adjuvant pembrolizumab compared placebo after surgery in patients clear cell renal carcinoma at an increased risk recurrence. reported here, additional 6 months follow-up, was designed to assess longer-term efficacy and safety versus placebo, as well secondary exploratory endpoints.In multicentre, randomised, double-blind, placebo-controlled, phase 3 trial, adults aged 18 years or older recurrence...
We evaluated the clinical significance of lymphovascular invasion in transurethral resection bladder tumor specimens patients with newly diagnosed T1 urothelial carcinoma bladder.Enrolled study were 118 who underwent between 2001 and 2007. Patient records retrieved from a prospectively maintained cancer database. correlation other clinicopathological features, impact on disease recurrence, progression metastasis.Lymphovascular was histologically confirmed 33 (28.0%). While correlated grade...
A prospective, randomized controlled trial was conducted to evaluate the efficacy of nerve-sparing radical hysterectomy (NSRH) in preserving bladder function and its oncologic safety treatment cervical cancer. From March 2003 November 2005, 92 patients with cancer stage IA2 IIA were randomly assigned for surgical conventional (CRH) or NSRH, 86 finally included analysis. Adequacy nerve sparing, radicality, function, assessed by quantifying fibers paracervix, measuring extent paracervix...
Objectives The aim of this study was to investigate the expression two commonly altered genes ERG and PTEN in prostate cancer (PC) evaluate their prognostic significance. Despite conflicting published results, TMPRSS2-ERG gene fusion loss are generally considered unfavorable markers for PC progression. Materials Methods Of 762 prostatic adenocarcinoma specimens obtained from radical prostatectomy, 613 without neoadjuvant hormone therapy were included tissue microarrays quantitatively...
Abstract The World Health Organization/International Society of Urological Pathology (WHO/ISUP) grading renal cell carcinoma (RCC) is classified from grade 1–4, regardless subtype. National Comprehensive Cancer Network (NCCN) guidelines (2022) state that if there an adverse pathological feature, such as 3 or higher RCC in stage 1 patients, more rigorous follow-up imaging recommended. However, the do not provide specific treatment policies by tumor grade. Therefore, this study attempted to...
OBJECTIVE To define the prognostic relevance of capsular involvement (invasion with no penetration) and collecting‐system invasion in patients stage I (pT1N0M0) II (pT2N0M0) renal cell carcinoma (RCC), by evaluating outcome treated nephrectomy. PATIENTS AND METHODS In all, 519 from a kidney cancer database nephrectomy for RCC between 1985 2005 were assessed retrospectively. The primary endpoint was recurrence‐free survival time. examined using univariate multivariate analysis. RESULTS...
Tumor vascularity is a potential predictor of treatment outcomes in metastatic renal cell carcinoma (mRCC), and contrast enhancement tumors computed tomography (CT) correlated significantly with microvessel density. In this study, the authors investigated whether tumor contrast-enhanced CT (CECT) useful for predicting patients mRCC who are receiving antiangiogenic therapy.Attenuation values were reviewed retrospectively on CECT images all lesions 66 from February 2007 to November 2008. All...
The treatment of metastatic renal cell carcinoma (mRCC) has recently evolved from being predominantly cytokine-based to the use targeted agents, which include sorafenib, sunitinib, bevacizumab (plus interferon alpha [IFN-α]), temsirolimus, everolimus, pazopanib, and most recently, axitinib.Improved understanding molecular pathways implicated in pathogenesis RCC led development specific therapies for treating disease.In Korea, it been 5 years since therapy became available mRCC.Thus, we now...
The international, phase 3 COMPARZ study demonstrated that pazopanib and sunitinib have comparable efficacy as first-line therapy in patients with advanced renal cell carcinoma, but safety quality-of-life profiles favor pazopanib. Our report analyzed Asian non-Asian subpopulations. Patients were randomized 1:1 to receive 800 mg once daily (continuous dosing) or 50 6-week cycles (4 weeks on, 2 off). Safety population was composed of 363 703 patients. had similar duration exposure either drug...
We investigated the safety and efficacy of a methotrexate, vinblastine, doxorubicin cisplatin (M-VAC) combination regimen as second-line chemotherapy for patients with advanced or metastatic transitional cell carcinoma who failed first-line gemcitabine (GC) chemotherapy. Thirty had progressed relapsed after GC treatment were enrolled in this study. The major toxicities neutropaenia thrombocytopaenia. A grade 3 4 occurred 19 (63.3%) thrombocytopaenia developed nine (30.0%). There no...
Pelvic exenteration offers the last chance of cure for some advanced or recurrent gynecologic malignancy patients. The aim this prospective study was to analyze factors associated with recurrence and survival after pelvic exenteration.Forty-six women malignancies were enrolled between July 2001 February 2006. All surgery performed by same gynecological oncologist.Two patients excluded due discovery peritoneal disease during surgery. Multivariate analysis showed that a tumor size >4 cm only...
Objectives To determine the potential association between HPV infection and squamous cell component of urothelial carcinoma (UC) bladder to validate p16 overexpression as a surrogate marker for in these cancers among Koreans. Methods We analyzed presence using an HPV-DNA chip expression immunohistochemistry 47 subjects July 2001 March 2011. The study group (n = 35) included patients with differentiation UC bladder. control 12) metaplasia Results Baseline characteristics groups were similar....
Purpose To assess the risk factors of positive surgical margins (PSM) and influence margin status on recurrence in pT1 clear cell renal carcinoma (RCC) following partial nephrectomy (PN). Materials Methods Patients (1,831) with pathologically confirmed stage T1 RCC were retrospectively analyzed PN at eight institutions Korea between 1999 2011. Demographics, operative data, pathological status, site analyzed. Results Resection 31 patients (1.7% cohort) final pathology. None...
Purpose This descriptive study assessed the current trends in incidence of urological cancers and patient survival Korea. Materials Methods In this nationwide retrospective observational based on data from Korea National Cancer Incidence Database (KNCIDB), analyzed age-standardized rates (ASRs) annual percentage changes (APCs) kidney, bladder, prostate, testicular, penile as well cancer renal pelvis ureter between 1999 2012. The relative (RSRs) were calculated for patients diagnosed 1993...
We evaluated prognostic risk factors of recurrence-free survival (RFS), metastasis-free (MFS), cancer-specific (CSS), and overall (OS) outcomes in patients with non-metastatic renal cell carcinoma (nmRCC) after curative nephrectomy during long-term-follow-up. The medical records 4260 nmRCC who underwent between 2000 2012 from five Korean institutions followed-up postoperative 1-month until December 2017 were retrospectively analyzed for RFS, MFS, OS, CSS. During the median 43.86 months...
Abstract Background and Objectives Metastatic renal cell carcinoma to the pancreas (PM‐RCC) is infrequent; we sought describe characteristics of PM‐RCC analyze outcome following treatment. Methods Data 3107 mRCC patients treated between 1992 2007 from Korean Renal Cancer Study Group database were obtained identify 300 (9.7%) patients. Characteristics survival analyzed compared rest mRCC, according timing metastasis surgical treatments received. Results was younger at initial diagnosis (55.0...
Bladder cancer, especially muscle-invasive bladder cancer (MIBC), poses significant treatment challenges due to its aggressive nature and poor prognosis, often necessitating cisplatin-based chemotherapy. While cisplatin effectively reduces tumor burden, nephrotoxic effects, specifically cisplatin-induced acute kidney injury (AKI), limit clinical use. This study investigates SH3YL1 as a potential biomarker for progression AKI. Plasma urine levels were measured in patients undergoing...
OBJECTIVE To investigate the clinical outcome using ureteric stents to manage obstruction in advanced non‐urological malignancies. PATIENTS AND METHODS We retrospectively reviewed use of (Endo‐sof, Cook Urological, Spencer, IN, USA) placed for malignant from June 2001 September 2006. The and radiological variables predicting failure stent insertion, functional death were analysed. RESULTS In all, 86 patients with a treated by stenting; 13 (15%) had retrograde remaining 73, 12 (16%) failures...
As patients with prostate cancer have a long life expectancy, there is increasing interest in predicting the risk of development second primary (SPC), and we therefore designed this study to estimate overall developing SPCs among Korean patients. We used population-based cohort from Central Cancer Registry composed 55,378 men diagnosed first between 1993 2011. Standardized incidence ratios (SIRs) were analyzed by age at diagnosis, latency period, period type initial treatment. Survival...
This study evaluated the effects of metastasectomy on overall survival (OS) and progression-free (PFS) in metastatic renal cell carcinoma (mRCC) according to organs. The medical records (2005–2017) 273 patients with mRCC were analyzed retrospectively evaluate OS PFS organs their states. Cox proportional hazard model was used determine prognostic significance metastasectomy. Kaplan-Meier curve log-rank test compare groups different modalities at a statistical p2.0) for both (p<0.05)....